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Abstract
Background
Routine immunisation with pneumococcal conjugate vaccines (PCV7/10/13) has reduced
invasive pneumococcal disease (IPD) due to vaccine serotypes significantly. However, an
increase in disease due to non-vaccine types, or serotype replacement, has been observed.
Serotypes’ individual contributions to IPD play a critical role in determining the overall effects
of PCVs. This study examines the distribution of pneumococcal serotypes in children to
identify leading serotypes associated with IPD post-PCV introduction.
Methods
A systematic search was performed to identify studies and surveillance reports (published
between 2000 and December 2015) of pneumococcal serotypes causing childhood IPD
post-PCV introduction. Serotype data were differentiated based on the PCV administered
during the study period: PCV7 or higher valent PCVs (PCV10 or PCV13). Meta-analysis
was conducted to estimate the proportional contributions of the most frequent serotypes in
childhood IPD in each period.
Results
We identified 68 studies reporting serotype data among IPD cases in children. We analysed
data from 38 studies (14 countries) where PCV7 was administered and 20 (24 countries)
where PCV10 or PCV13 have been introduced. Studies reported early and late periods of
PCV7 administration (range: 200113). In these settings, serotype 19A was the most pre-
dominant cause of childhood IPD, accounting for 21.8% (95%CI 18.625.6) of cases. In
countries that have introduced higher valent PCVs, study periods were largely representa-
tive of the transition and early years of PCV10 or PCV13. In these studies, the overall sero-
type-specific contribution of 19A was lower (14.2% 95%CI 11.118.3). Overall, non-PCV13
serotypes contributed to 42.2% (95%CI 36.149.5%) of childhood IPD cases. However,
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regional differences were noted (57.8% in North America, 71.9% in Europe, 45.9% in West-
ern Pacific, 28.5% in Latin America, 42.7% in one African country, and 9.2% in one Eastern
Mediterranean country). Predominant non-PCV13 serotypes overall were 22F, 12F, 33F,
24F, 15C, 15B, 23B, 10A, and 38 (descending order), but their rank order varied by region.
Conclusion
Childhood IPD is associated with a wide number of serotypes. In the early years after intro-
duction of higher valent PCVs, non-PCV13 types caused a considerable proportion of child-
hood IPD. Serotype data, particularly from resource-limited countries with high burden of
IPD, are needed to assess the importance of serotypes in different settings. The geographic
diversity of pneumococcal serotypes highlights the importance of continued surveillance to
guide vaccine design and recommendations.
Introduction
Streptococcus pneumoniae is the major cause of serious invasive diseases such as bacterial pneu-
monia, septicaemia, and meningitis in young children worldwide. An estimated 14.5 million
cases of invasive pneumococcal disease (IPD) occurred globally in 2000 before introduction of
pneumococcal conjugate vaccines (PCVs). Widespread availability of PCVs has reduced the
burden of IPD substantially, from over 800,000 annual deaths before PCV introduction to
541,000 deaths in 2008 [1, 2]. Although two formulations of PCVs are available to protect
against disease, S. pneumoniae still poses a significant burden on individuals and healthcare
systems.
PCVs have been largely effective in reducing IPD associated with serotypes included in cur-
rently available formulations. Yet, concerns exist about their long-term effects since these con-
tain a limited number of serotypes and the potential role of non-vaccine serotypes. The first
PCV, licensed in 2000, offered protection against 7 serotypes (4, 6B, 9V, 14, 18C, 19F, 23F). By
2015, PCV7 had been replaced, and PCV10 (PCV7 + 1, 3, 7F) or PCV13 (PCV10 + 19A, 6A, 3)
have been introduced in over 130 countries [3, 4]. Before the introduction of PCVs, vaccine-
targeted serotypes were associated with a 8288% of IPD in North America, 7288% in
Europe, 6879% in Oceania, 5882% in Latin America, 4977% in Africa, and 5274% in
Asia [5]. After the introduction and scale up of PCV7 in routine immunisation programmes,
IPD caused by these 7 serotypes decreased significantly in children and other age groups [6, 7].
Nasopharyngeal carriage of S. pneumoniae, which can lead to invasive disease [8], was also dra-
matically impacted by PCVs. Studies indicated that PCVs reduced the prevalence of targeted
serotypes among carriers [9] to the extent that these strains have nearly disappeared in some
settings in both the vaccinated and unvaccinated persons [10].
In light of global efforts for universal immunisation with PCV, it is important to examine
which serotypes are associated with IPD in the post-PCV era to gain insights into the evolv-
ing epidemiology of S. pneumoniae. Serotype replacement, an increase in incidence of disease
due to serotypes [8] not included in PCV7, was noticed among young children using data
from 21 large surveillance systems [11]. In these industrialised settings, by the 7th year of
PCV7, the rate ratio of vaccine-related IPD (RR 0.03 95%CI 0.010.10) decreased substan-
tially as compared to the ratio of non-PCV7 types (RR 2.81 95%CI 2.123.71). Thus, there is
a clear need for close monitoring of serotypes causing IPD to inform public health actions
S. pneumoniae serotype distribution in childhood IPD post-PCV
PLOS ONE | https://doi.org/10.1371/journal.pone.0177113 May 9, 2017 2 / 20
data and materials. MK is an employee of Sanofi
Pasteur. EB, LG, HN have not received funding
from Sanofi Pasteur as investigators in clinical
trials and declare no conflict of interest.
[8]. We aimed to systematically assess and describe the global distribution of serotypes caus-
ing IPD in young children after the introduction of PCVs to better understand the contribu-
tion of individual serotypes, including non-vaccine types and inform recommendations for
vaccine use.
Methods
Search methods and inclusion criteria
We conducted a systematic review of the literature according to the PRISMA guidelines. We
searched electronic medical databases for studies and surveillance reports (published between
1 January 2000 and 31 December 2015) reporting serotype data from children with IPD after
the introduction of a PCV in the study area. Search strategies with database-specific MeSH
and free search terms were developed with the assistance of a medical librarian for Medline,
Embase, and Global Health (via Ovid); EMRO, SEARO, and WPRO regional databases
(Global Health Library), LILACS, and Web of Science. Strategies were designed to retrieve rec-
ords that included the following terms: Streptococcus pneumoniae and, IPD or syndromes, and
vaccines, and serotypes (search strategies are available in S1 Table).
We included peer-reviewed studies and annual surveillance reports from Department of
Health websites from countries from which the electronic medical databases retrieved national
surveillance publications. IPD was defined as the identification of S. pneumoniae from a nor-
mally sterile site (e.g. blood, cerebrospinal, pleural effusions, or joint fluid) in children. No
language restrictions or publication type were imposed at this stage. We also scanned the refer-
ence list of included studies to identify any additional studies. Eligibility criteria were as
described in Box 1, which were modified from previous reviews assessing the serotype distri-
bution in childhood IPD [5, 11].
Data collection and analysis
Two reviewers (EB, LG) independently reviewed identified publications and extracted rele-
vant data into a template (Microsoft Excel), which was piloted before use. Datathief III soft-
ware (http://datathief.org/) was used to extract data from images. Study periods were
classified according to the PCV administered during the study period as either PCV7 or
higher valent (PCV10 or PCV13, hereafter PCV10/13). From each study included in analy-
sis, data for young children (<5 years) was preferred, if other age groups were available to
minimise bias. Non-vaccine types were those currently not included in PCV13 (non-
PCV13).
Meta-analysis. Serotype-specific percentages were calculated for each study (% serotype
x = total number of cases serotype x over total IPD isolates with serotype data x 100). Ser-
ogroup data were not redistributed into serotypes. Using metan in Stata 13 (Statacorp, Col-
lege Station, TX), pooled estimates and 95% confidence intervals (95%CI) were calculated for
serotype-specific proportions using the transformed log of the proportion and random effects
model (DerSimonian-Laird method). A continuity correction was used to include data from
studies with zero counts in independent meta-analyses. If there were multiple studies from
the same setting, the most representative of childhood IPD (i.e. larger sample size, or report-
ing data for any IPD rather than a single syndrome) was included in meta-analysis. Most data
for settings where PCV10 or PCV13 have been introduced were from countries that had tran-
sitioned from PCV7, except Brazil, Chile, and Colombia. The first year of PCV10 or PCV13
introduction for these 3 Latin American countries was excluded from analyses to allow time
for scaling up of vaccine uptake. For other settings, data from the transition year from PCV7
to higher valent PCVs was included in meta-analysis, as it was not possible to exclude this
S. pneumoniae serotype distribution in childhood IPD post-PCV
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year from analysis for all studies. We used data exclusively for years with either PCV7 or the
current higher valent PCV, except when disaggregation was not possible. We report overall
and regional pooled estimates with 95%CIs for vaccine types and individual non-PCV13
types causing at least 1% of IPD in the dataset of countries that have introduced PCV10 or
PCV13.
Box 1. Eligibility criteria for this review
Inclusion
• Observational studies or annual national surveillance reports from selected Depart-
ments of Health from settings with PCV uptake of at least 25% during the study period
described
• Studies reporting at least 20 serotyped isolates overall and with at least 50% of reported
IPD cases were serotyped
• Study reports data on different serogroups/types for invasive disease (defined as iso-
lates from normally sterile sites) in children
• Study population was representative of the general population, not a selected group
with specific co-morbidities
• Surveillance conducted for at least 12 continuous months
Exclusion
• Case reports, narrative reviews, quarterly or province-level surveillance reports, if
annual and/or national were available
• Serotype data from studies with high risk of bias: e.g. studies focused on serotypes
from severe cases, most frequent types, or antimicrobial resistance
• Data for years after PCV introduction are not extractable independently or the study
does not provide a description of PCV use in the area
• Data only reported for serotypes included in PCVs (PCV7, PCV10, PCV13)
• Serotype data included isolates obtained from non-sterile sites (e.g. nasopharynx) or
not extractable specifically for otherwise healthy children (i.e. study population
includes all immunocompromised population or adults)
• Data overlap with other studies included in the analysis (Studies with the longest study
period or larger sample size were preferred)
Serotypes in Pneumococcal conjugate vaccines
PCV7: 4, 6B, 9V, 14, 18C, 19F, 23F
PCV10: PCV7 + 1, 5, 7F
PCV13: PCV10 + 3, 6A, 19A
Non-PCV13: those not included in PCV13
S. pneumoniae serotype distribution in childhood IPD post-PCV
PLOS ONE | https://doi.org/10.1371/journal.pone.0177113 May 9, 2017 4 / 20
Results
Literature review
We identified 5,912 records through databases search and identified 138 articles for full text
examination (Fig 1). Of these, 64 [6, 7, 12–73] articles met our pre-defined eligibility criteria
and we identified an additional 4 surveillance reports [74–77] from online searches.
Fig 1. PRISMA flowchart—Literature review process.
https://doi.org/10.1371/journal.pone.0177113.g001
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Characteristics of included publications
A total of 27 countries were represented in the 68 publications included in the review. Surveil-
lance data were retrieved from online reports for Latin America (SIREVA II reports 2009–12,
considered as 1 publication), Scotland (UK), Australia, New Zealand, and Singapore. Studies
identified overlapping geographic, time period or for individual clinical syndromes were
excluded from meta-analyses (details in S2 Table).
Main characteristics of studies included in meta-analysis are available in Table 1. Eight pub-
lications reported serotype data for years after both time periods after PCV7 and PCV10/13
implementation. These were extracted separately for analysis. After classification of the studies,
we analysed 67 data points assessing childhood IPD, primarily from North America (n stud-
ies = 17), Europe (n = 28), and Latin America (n = 11), but also from Western Pacific (n = 8),
Eastern Mediterranean (n = 2) and Africa (n = 1).
We analysed serotype data from 7,366 IPD isolates (range: 33609) from 38 studies in 14
countries for study periods when PCV7 was administered (Table 1). Study periods ranged
from 2001, in the USA [19, 21, 38, 61, 72] until 2013 in Japan [24, 40, 66]. We excluded studies
reporting<25% PCV coverage, but studies included serotype data from different uptake levels.
For instance, from settings where PCV7 had been recently licensed, introduced into national
immunisation programmes, or it was largely available through the private system, for instance,
in Spain [16, 17, 22, 34, 52, 56, 57, 59, 60, 69], Portugal [12], and Austria [58]. Other studies
were from settings where vaccine uptake was high or PCV was recommended universally in
the study setting, such as in Canada [18, 26, 43], USA, UK, Colombia (Bogota) [55], France
[13].
We analysed 20 publications from 24 countries where PCV10 or PCV13 have been intro-
duced. The Americas region was the most represented (n = 12 countries). PCV10 was the pri-
mary vaccine in 6 countries (Brazil, Chile, Colombia, Ecuador, Peru, and the Netherlands),
while PCV13 had been introduced in the remaining 18. Most study periods included the year
of transition from PCV7 or the year after introduction of the current higher valent. PCV. A
total of 5,469 IPD isolates with serotype data were included in meta-analysis. The number of
isolates in individual studies ranged from 23 to 886. The countries with the largest number of
isolates were Canada and South Africa (n = 886 and 839, respectively). Six publications
reported data for fewer than 50 isolates and an additional 8 reported less than 100 cases.
Serotype distribution among paediatric IPD cases following PCV
introduction
PCV-targeted serotypes. In studies where PCV7 was administered, serotypes included in
the heptavalent conjugate vaccine accounted for an overall 14.8% (95%CI 11.419.1) of child-
hood IPD cases. In studies with study periods after higher valent PCVs were introduced, the
proportional contribution of these seven serotypes to IPD in children was 12.5% (95%CI
8.817.7). In the latter, all countries, except the Netherlands, identified PCV7 types. PCV7
types were most frequently isolated from childhood IPD cases in Latin America, Africa, and
Eastern Mediterranean regions (32.5%, 25.5%, 62.6% of IPD cases, respectively). Conversely,
PCV7 types accounted for lower proportions of IPD in North America, Europe, and the West-
ern Pacific, between 3.45.8%, after introduction of PCV10 or PCV13. Fig 2 and Tables 2 and
3 show the overall meta-estimate and regional stratifications results per period.
PCV10-specific serotypes. Serotypes 1, 5, and 7F were identified in all studies with peri-
ods of PCV7 implementation, accounting for an overall 16.3% (95%CI 13.591.8) of child-
hood IPD cases. These serotypes comprised 9.2% (95%CI 6.912.2) in settings where PCV10
or PCV13 have been introduced; which were reported in most countries (except France and
S. pneumoniae serotype distribution in childhood IPD post-PCV
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Table 1. Main characteristics of studies included in the review and meta-analyses.
Last author (publication
year)
Country PCV Introduction year Study years (PCV uptake) Isolates PCV13 types (%) Non-PCV13 (%)
Rendi-Wagner (2009) Austria PCV7 2001* 2005–06 (25%) 36 97.2 2.8
Lepoutre (2015) France PCV7 2003*, 2006† 2008–09 (83–95%) 483 71.4 28.6
Varon (2015) France PCV7 2006† 2008–09 (>86%) 388 67.5 32.5
van der Linden (2015) Germany PCV7 2006† 2007–10 (80–85%) 542 68.1 31.9
Knol (2015) Netherlands PCV7 2006† 2008–11 (94–95%) 128 52.3 47.7
Steens (2013) Norway PCV7 2006† 2006–10 (86–92%) 165 69.1 30.9
Aguiar (2008) Portugal PCV7 2001* 2003–05 (33%) 90 85.6 14.4
Aristegui (2007) Spain PCV7 2001* 2002–03 (28–45%) 77 88.3 11.7
Barricarte (2007) Spain PCV7 2001* 2001–05 (45%) 85 87.1 12.9
Calbo (2006) Spain PCV7 2001* 2002–04 (34%) 64 78.1 21.9
Guevara (2014) Spain PCV7 2001* 2004–09 (25–61%) 106 78.3 21.7
Munoz-Almagro (2011) Spain PCV7 2001* 2009§ 130 80.0 20.0
Perez-Trallero (2009) Spain PCV7 2001* 2002–07 (~50%) 45 86.7 13.3
Picazo (2011) Spain PCV7 2001* 2007–09 (~50%) 330 79.1 20.9
Rodriguez (2011) Spain PCV7 2006† 2007–09 (94.5%) 366 74.9 25.1
Salleras (2009) Spain PCV7 2001* 2005–07 (35%) 240 77.9 22.1
Vila-Corcoles (2013) Spain PCV7 2001* 2002–09 (13–47%) 65 84.6 15.4
Ceyhan (2011) Turkey PCV7 2008† 2008–10§ 146 77.4 22.6
Miller (2011) UK PCV7 2006† 2008–10§ 528 69.7 30.3
Moore (2014) UK PCV7 2006† 2006–10 (92–87%) 65 49.2 50.8
Parra (2013) Colombia PCV7 2009 2010–11 (69.9%) 84 70.2 29.8
Bettinger (2010) Canada PCV7 2005† 2006–07 (80–90%) 212 69.8 30.2
De Wals (2012) Canada PCV7 2004 2007 (>90%) 113 63.7 36.3
Kellner (2009) Canada PCV7 2002 2003-07(87–91%) 67 76.1 23.9
Black (2007) USA PCV7 2000† 2001–05 (86%) 84 34.5 65.5
Bruce (2015) USA PCV7 2001† 2005–08§ 126 61.9 38.1
Byington (2005) USA PCV7 2000† 2001–03§ 105 74.3 25.7
Croney (2013) USA PCV7 2000† 2002–10§ 157 60.5 39.5
Hsu (2010) USA PCV7 2000† 2001-02/06-07§ 130 66.2 33.8
Kaplan (2013) USA PCV7 2000† 2007–09§ 609 67.7 32.3
Pilishvili (2010) USA PCV7 2000† 2006–07§ 519 67.9 32.1
Schutze (2004) USA PCV7 2000† 2001–03§ 75 77.3 22.7
Sharma (2013) USA PCV7 2000† 2008–09§ 47 59.6 40.4
Weatherholtz (2010) USA PCV7 2000† 2001–06§ 115 76.5 23.5
Williams (2011) Australia PCV7 2001*, 2005† 2006–07§ 201 67.2 32.8
Chiba (2014) Japan PCV7 2010/11* 2011–12 (50–90%) 302 55.0 45.0
Ishiwada (2014) Japan PCV7 2010*, 2011† 2012–13§ 33 51.5 48.5
Suga (2015) Japan PCV7 2010* 2011–13 (89%) 308 68.8 31.2
von Gottberg (2013) South Africa PCV13 2011† 2011–12§ 839 57.3 42.7
Al-Sheikh (2014) Saudi Arabia PCV13 2010† 2009–12§ 78 85.9 14.1
Shibl (2012) Saudi Arabia PCV13 2010§ 108 94.4 5.6
Varon (2015) France PCV13 2010† 2012–13 (>92%) 181 17.7 82.3
van der Linden (2015) Germany PCV13 2009 Dic† 2010–14 (80–85%) 567 35.4 64.6
Knol (2015) Netherlands PCV10 2011† 2011–14 (94–95%) 57 21.1 78.9
Steens (2013) Norway PCV13 2011† 2011–12 (92%) 47 55.3 44.7
Guevara (2014) Spain PCV13 2010 2010–13 (78%) 25 52.0 48.0
(Continued )
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Singapore). In this most recent period, the contributions to paediatric IPD cases due to
PCV10-specific serotypes were similar in all regions (approximately 89%), except in the
Western Pacific (4.6%).
PCV13-specific serotypes. In both periods, the most frequent PCV13 type was 19A, fol-
lowed by 3, and then 6A. Serotype 3 accounted for 56% of childhood IPD cases after the
introduction of either PCV, while 6A was associated with approximately 3% of all cases. In
studies from countries where PCV10 or PCV13 have been introduced, serotype 19A accounted
for 14.2% (95% CI 11.118.3%) of childhood IPD cases across all regions (and at least 10% in
each of the regions).
Non-PCV13. There was wide-variation in the number of non-PCV13 strains reported. In
addition to the 16 non-PCV13 types included in meta-analysis, at least 1 case was reported for
over 60 different serotypes currently absent in any of the PCV formulations (a list is provided
in the S3 Table).
The overall contribution of non-PCV13 types to IPD in children was 29.4% (95%CI
26.832.4) in periods of PCV7 administration and 42.2% (95%CI 36.149.5) in studies where
higher valent PCVs have been introduced. In each period, differences between the individual
proportional contribution of non-PCV13 serotypes to childhood IPD were small and their
Table 1. (Continued)
Last author (publication
year)
Country PCV Introduction year Study years (PCV uptake) Isolates PCV13 types (%) Non-PCV13 (%)
Moore (2014) UK PCV13 2010† 2010–13§ 48 37.5 62.5
Scotland Surveillance UK PCV13 2010† 2010–15§ 206 19.9 80.1
Waight (2015) UK PCV13 2010† 2013–14§ 247 14.2 85.8
SIREVA (Brazil) Brazil PCV10 2010‡ 2011–12 (81.5%) 416 68.8 31.3
SIREVA (Chile) Chile PCV10 2011‡ 2012 (54.0%) 168 72.6 27.4
SIREVA (Colombia) Colombia PCV10 2010‡ 2011–12 (69.8%) 208 74.0 26.0
SIREVA (Costa Rica) Costa Rica PCV13 2011† 2011–12 (78.0%) 38 76.3 23.7
SIREVA (Ecuador) Ecuador PCV10 2010† 2011–12 (71.0%) 62 80.6 19.4
SIREVA (El Salvador) El Salvador PCV13 2011† 2011–12 (98.1%) 31 74.2 25.8
SIREVA (Mexico) Mexico PCV13 2011† 2012 (97.8%) 105 66.7 33.3
SIREVA (Panama) Panama PCV13 2011† 2011–12 (61.8%) 68 88.2 11.8
SIREVA (Peru) Peru PCV10 2011† 2011–12 (81.9%) 23 69.6 30.4
SIREVA (Uruguay) Uruguay PCV13 2010† 2010–12 (92.0%) 96 50.0 50.0
Demczuk (2013) Canada PCV13 2010† 2010–12 (74–90%) 886 55.5 44.5
Bruce (2015) USA PCV13 2010† 2010–13 (86–96%) 52 25.0 75.0
Kaplan (2013) USA PCV13 2010† 2010–11§ 283 56.5 43.5
Moore (2015) USA PCV13 2010 2012–13 (63–76%) 177 19.2 80.8
Australia Surveillance Australia PCV13 2011† 2012§ 184 43.5 56.5
Nakano (2015) Japan PCV13 2013† 2014§ 126 28.6 71.4
N Zealand Surveillance New
Zealand
PCV13 2014 2014–15 (93%) 78 51.3 48.7
Singapore Surveillance Singapore PCV13 2010* 2011† 2012–14§ 65 86.2 13.8
Notes—Definitions for PCV uptake varied by study. Uptake is presented as reported in each study.
*PCV was first recommended, approved or licenced,
†Included in national immunisation programmes/Universal administration recommended
‡ First year of PCV implementation in the country. Settings where national or universal PCV administration is recommended, where eligible for inclusion.
§Data not reported.
https://doi.org/10.1371/journal.pone.0177113.t001
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overall ranking varied within regions (Tables 2 and 3). Based on data from countries where
PCV10 or PCV13 have been introduced, 22F was the most common serotype (5% of overall
childhood IPD cases analysed), followed by 12F, 15C, 24F, 33F (4% each). Combined, the lead-
ing non-PCV13 serotypes 22F, 12F, 33F accounted for 416% of IPD cases in children across
regions, except in the Eastern Mediterranean region. Notably, serotype 24F appears to be prev-
alent in Europe and Western Pacific regions, but not North America.
Contributions of serotypes to childhood IPD between periods
We compared the contribution of various serotypes to childhood IPD in the two sets of studies
(PCV7 implementation and PCV10 or PCV13 introduction). We observed decreases in the
percentage point differences in PCV7 types (-2.3%), PCV10-only strains (-7.1%) and 19A
(-7.6%). Changes observed between periods for overall meta-estimates of non-PCV13 types
were small. Comparisons between the regions with the longest history of PCV use (North
America, Europe, and Western Pacific) show variations in the percentage point reductions in
PCV13 serotypes among childhood IPD cases:-29.5%, -46.4%, and -13.8% in North America,
Europe, and Western Pacific regions, respectively. Notably, studies from these regions
reported a range of early and late periods of PCV7 use in individual study settings, while data
from countries that have introduced higher valent PCVs were largely representative of the
transition and early years of the vaccines. Non-PCV13 serotype 22F accounted individually for
at least 5% of childhood IPD in North America, an increase of approximately 2 percentage
points, compared to the post-PCV7 period. Similar changes in this serotype was also seen in
Europe and Western Pacific (+3%). Other non-PCV13 serotypes with an increase in their pro-
portional contribution to paediatric IPD after introduction of PCV10/13 differ between
Fig 2. Estimates of serotype-specific contributions to IPD in children (%, 95%CI) reported are based on random
effects model from meta-analysis of 3 or more studies, unless indicated [one study (*) or two (**)].
https://doi.org/10.1371/journal.pone.0177113.g002
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regions. For instance, serotype 38 (+2.7%) accounted for more childhood IPD cases in North
America while 12F and 15C (+3.7%) and 10A (+4.2%) were more prominent in Europe.
Discussion
This is the first study to comprehensively report S. pneumoniae serotype-specific contributions
to IPD in young children subsequent to the introduction of PCVs. Our estimates, based on a
systematic analysis of data available to-date indicate that, in countries that have introduced
higher-valent PCVs, approximately 42% (95%CI 3649) of childhood IPD cases were caused
by non-PCV13 serotypes. Our results provide insights into the relative importance of serotypes
in childhood IPD after widespread implementation of PCVs and highlight regional
differences.
It is well documented that routine immunisation with PCVs has led to significant decreases
in both colonisation and IPD by vaccine-targeted types in children and that it has indirectly
impacted non-targeted populations [78]. It was estimated that PCV7-targeted serotypes
accounted for 4982% of childhood IPD before PCV introduction [5]. We found that, after
PCV7 implementation, their proportional contribution was approximately 1119%. This is
consistent with other regional estimates, as prior to the introduction of PCV13 in Europe
PCV7-type IPD was approximately 19% among children based on data from 26 countries [79].
Table 2. Serotype-specific contributions (%) to paediatric IPD cases by region in studies with PCV7 implementation.
OVERALL
(N = 38)
LATIN AMERICA
(N = 1)
NORTH AMERICA
(N = 13)
EUROPE
(N = 20)
WESTERN PACIFIC
(N = 4)
PCV7 14.8 (11.4–19.1) * 38.1 (26.9–53.9) 8.6 (4.9–15.2) 16.8 (11.9–23.9) 27.5 (19.8–38)
PCV10-7 16.3 (13.5–19.8) * 10.7 (5.6–20.6) 13.6 (10.8–17) 24.9 (20.7–30) 1.5 (0.8–2.9)
PCV13 70.5 (67.6–73.5) * 70.2 (54.4–90.7) 66.8 (62.3–71.6) 74.3 (70.6–78.2) 62.5 (54.9–71.3)
19A 21.8 (18.6–25.6) * 6 (2.5–14.3) 28.9 (23–36.4) 18.7 (15.4–22.7) 25.9 (17.7–37.9)
3 4.9 (4.2–5.8) * 14.3 (8.1–25.2) 6.3 (5.1–7.8) 4.6 (4–5.4) 2.5 (1.4–4.6)
6A 3.1 (2.4–4.1) * 1.2 (0.2–8.5) 2.9 (1.5–5.6) 3.2 (2.2–4.5) 3 (2–4.5)
NON PCV13 29.4 (26.8–32.4) * 29.8 (20.1–44) 33.7 (29.4–38.7) 24.9 (21.7–28.8) 37.6 (30.1–46.9)
22F 3.5 (2.9–4.3) * 1.2 (0.2–8.5) 4.9 (4–6) 2.2 (1.5–3.3) 4 (2.8–5.6)
12F 2.3 (1.8–2.9) − 3.1 (1.6–6) 1.9 (1.5–2.4) * 0.3 (0–2.3)
33F 3.4 (2.6–4.6) − 4.8 (3.7–6.3) 3 (1.7–5.1) 2.1 (1.3–3.4)
24F 4 (3.4–4.8) * 1.2 (0.2–8.5) − 3.3 (2.5–4.5) ** 5 (3.1–8)
15C 2.8 (2.3–3.4) * 2.4 (0.6–9.5) 2.6 (1.7–3.8) 2.2 (1.7–2.9) 4.7 (3.3–6.7)
15B 2.4 (2–3) * 3.6 (1.2–11.1) 2.4 (1.6–3.5) 2.3 (1.8–3) ** 2.8 (1.8–4.6)
23B 1.7 (1.4–2.1) * 1.2 (0.2–8.5) 2 (1.4–2.8) 1.5 (1.1–2) −
10A 2.6 (2–3.3) − 2.5 (1.7–3.5) 2.5 (1.6–3.8) 2.5 (1.2–5.4)
38 2.3 (1.8–2.8) − 2.7 (1.8–4.2) 1.9 (1.4–2.7) 1.8 (1–3.2)
15A 1.8 (1.2–2.7) * 2.4 (0.6–9.5) 1.5 (1–2.3) 1.1 (0.8–1.6) 7.1 (5–10.2)
35B 1.2 (0.9–1.6) * 2.4 (0.6–9.5) 1.5 (0.9–2.6) 0.7 (0.4–1.1) 1.6 (0.8–3.1)
6C 2.8 (2.2–3.4) − 3.4 (2.4–4.8) 1.1 (0.7–1.7) ** 4.2 (2.7–6.8)
8 1.4 (1.1–1.9) * 2.4 (0.6–9.5) 0.9 (0.5–1.8) 1.6 (1.1–2.2) −
11A 1.3 (1–1.8) * 2.4 (0.6–9.5) 1.1 (0.6–2) 1.2 (0.8–1.7) ** 1.8 (0.7–4.5)
23A 1.6 (1.2–2.1) − 1.8 (1.2–2.7) 0.7 (0.4–1.2) ** 1.4 (0.2–9.1)
9N 0.9 (0.6–1.2) − 0.7 (0.4–1.3) 1 (0.6–1.7) −
Estimates of serotype-specific contributions to IPD in children (% 95%CI) reported are based on random effects model from meta-analysis of 3 or more
studies, unless indicated [one study (*) or two (**)].–indicates no data reported. Meta-analyses were conducted individually, thus the sum of each of the
serotypes in a category may exceed 100%
https://doi.org/10.1371/journal.pone.0177113.t002
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Subsequent to the introduction of higher valent PCVs, the proportional contribution of sero-
types targeted by PCVs continued to decrease, with differences across regions.
Concerns exist about optimum prevention of PCV13-types 3 and 19A−IPD in young chil-
dren. We estimated that serotype 3−specific contribution to childhood IPD was approximately
5% in the two PCV periods analysed. These estimates are noteworthy, as serotype 3 has been
associated with cases of vaccine failure [80]. Our meta-estimates also show the extent of 19A’s
predominant contribution to childhood IPD in different world regions after the introduction
of PCVs. Subsequent to the introduction of PCV7, 19A was consistently identified as the most
frequent serotype associated with childhood IPD cases in the Americas, Europe, and Western
Pacific regions (causing approximately 20% of cases). We also found an important contribu-
tion to childhood IPD cases of serotype 19A (14.2% 95%CI 11.118.3) in the early years of
higher valent PCVs. More recent data suggest different experiences regarding changes in the
contribution of 19A at the country level. In the USA, significant reductions of IPD after 5
years of use of PCV13 have been driven by decreases in 19A [81]. However, in other settings in
Europe, this serotype continues to pose challenges as a disease-causing strain despite wide-
spread use of PCVs [82, 83]. Differences in vaccine schedules and catch-up campaigns between
these settings, as well as time required to observe a decrease in disease due to vaccine-targeted
strains are key factors that will influence the epidemiology of S. pneumoniae strains. The
Table 3. Serotype-specific contributions (%) to paediatric IPD cases in settings that have introduced PCV10 or PCV13.
OVERALL
(N = 20)
LATIN AMERICA
(N = 1†)
NORTH AMERICA
(N = 4)
EUROPE
(N = 8)
WESTERN PACIFIC
(N = 4)
AFRICA
(N = 1)
EASTERN
MEDITERRANEAN
(N = 2)
PCV7 12.5 (8.8–17.7) 32.5 (25.5–41.3) 3.4 (2.5–4.5) 4.4 (3.3–5.7) 5.8 (1.6–21.1) * 25.5 (22.3–29.2) ** 62.6 (46.3–84.7)
PCV10-7 9.2 (6.9–12.2) 10.1 (5–20.4) 7.9 (4.5–13.9) 10.1 (6.6–15.4) 4.6 (1.5–14) * 9.8 (7.9–12.2) ** 8.9 (1–81.8)
PCV13 49.1 (42.3–56.9) 71.2 (65.9–77) 37.3 (25.4–54.7) 27.9 (19.9–39.1) 48.7 (31.6–74.8) * 57.3 (52.4–62.6) ** 91 (78.2–100)
19A 14.2 (11.1–18.3) 12.5 (7.7–20.2) 20.8 (13.3–32.6) 11.3 (7.6–17) 29.6 (20.3–43.1) * 11.4 (9.3–13.9) ** 6.2 (3.4–11.2)
3 5.3 (4.2–6.7) 6.7 (4.7–9.7) 6.1 (3.9–9.3) 4.7 (3.6–6.1) 7.1 (3.4–14.9) * 2 (1.3–3.2) * 2.2 (0.8–5.8)
6A 3.2 (2.1–4.9) 5.5 (4.2–7.1) ** 1 (0.6–1.8) 1 (0.5–2) * 0.5 (0.1–3.8) * 8.5 (6.8–10.8) ** 4.9 (2.2–11.3)
NON-PCV13 42.2 (36.1–49.5) 28.5 (23.4–34.7) 57.8 (41.6–80.4) 71.9 (63.1–82) 45.9 (30.9–68.2) * 42.7 (38.5–47.4) * 9.2 (3.7–22.9)
22F 5.3 (4.2–6.7) 2.3 (1.4–3.7) 6.9 (4.5–10.4) 5.2 (3.6–7.5) 7.4 (4.6–12) − −
12F 4.3 (3.5–5.3) 4 (2.8–5.7) ** 3.3 (1.3–8.3) 5.6 (4.4–7) − * 4 (2.9–5.6) * 1.3 (0.2–9.1)
33F 4.5 (3.4–5.9) ** 2 (0.8–4.8) 4.9 (2.2–10.8) 4.9 (3.3–7.4) 4.3 (2.5–7.5) − −
24F 4.2 (2.6–6.8) 2.4 (1.6–3.8) − 6.7 (3.8–11.9) * 3.9 (0.1–12.4) − −
15C 4 (3.1–5) 1.5 (0.8–2.7) 3.9 (2.4–6.5) 5.9 (4.4–7.8) * 4.3 (2.2–8.7) − −
15B 3.7 (3.1–4.4) 2.5 (1.5–4.3) 4.2 (2.3–7.8) 3.7 (2.6–5.2) ** 3.3 (1.7–6.7) * 4.3 (3.1–5.9) −
23B 3.4 (2.6–4.3) 2.4 (1.4–4.1) 3 (2–4.4) 4.1 (2.6–6.5) ** 3.9 (2.1–7.3) − * 1.3 (0.2–9.1)
10A 3.4 (2.2–5.4) 1.3 (0.8–2.3) ** 2.6 (1.7–3.8) 6.7 (3.7–12.4) ** 3 (1.6–5.8) − −
38 3.4 (2.4–4.8) 1.8 (0.6–5.5) ** 5 (1.7–14.3) 3.2 (1.8–5.6) ** 0.7 (0.2–2.6) − −
15A 2.9 (1.9–4.4) 1.4 (0.8–2.5) 3.3 (1.5–7.4) 3.9 (1.9–7.9) ** 3 (0.2–38.9) − −
35B 2.6 (1.8–3.8) 1.2 (0.2–6.4) 4.5 (1.7–11.4) 1.4 (0.9–2.3) ** 3.9 (2.2–6.9) − −
6C 2.4 (1.8–3) 2.4 (1.6–3.7) 2.3 (1.6–3.3) 1.6 (0.7–3.6) 3 (1.2–7.1) − −
8 2.2 (1.3–3.8) 1.2 (0.6–2.3) ** 1.5 (0.9–2.5) 2.9 (1.3–6.2) * 3.8 (1.2–11.9) * 8.3 (6.6–10.5) * 1.3 (0.2–9.1)
11A 2 (1.6–2.6) 2.2 (1.5–3.3) ** 2.5 (1.6–3.7) 1.7 (1.1–2.6) ** 0.7 (0.2–2.6) − −
23A 2 (1.6–2.6) 2 (1.2–3.6) 2.2 (1.5–3.2) 1.6 (1–2.5) 2.4 (1.1–5) − * 2.6 (0.6–10.2)
9N 1.3 (1–1.8) 1.3 (0.6–2.8) ** 1.3 (0.7–2.4) 1.3 (0.7–2.4) ** 1.5 (0.5–4.7) * 1.8 (1.1–3) −
Estimates of serotype-specific contributions to IPD in children (% 95%CI) reported are based on random effects model from meta-analysis of 3 or more
studies, unless indicated [one study (*) or two (**)].–indicates no data reported.
†10 countries from the SIREVA surveillance network. Meta-analyses were conducted individually, thus the sum of each of the serotypes in a category may
exceed 100%
https://doi.org/10.1371/journal.pone.0177113.t003
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estimated contributions of serotypes to childhood IPD in this study emphasise the need for a
better understanding of factors associated with disease due to vaccine types, especially as
PCV10 and PCV13 continue to be administered worldwide.
Widespread use of PCVs has resulted in dramatic reductions of IPD associated with vaccine
serotypes among young children in high-income countries in North America, Europe, and the
Western Pacific [11, 51, 79]. Knowledge of the serotypes that are associated with IPD among
the target population is important for the development of new vaccines that extend protection
against non-PCV13, which could also affect other age groups. We found that subsequent to
the introduction of higher valent PCVs in North America and Europe, approximately half of
childhood IPD cases were due to serotypes for which there is no protection via immunisation.
Serotypes likely to provide further reductions in disease are 22F, 33F, 15B, 38, and 35B (25%
combined) in North America. In Europe, the leading disease-causing non-PCV13 strains were
12F, 10A, 24F, 22F, and 15C, accounting for 30% of IPD. Serotypes 12F, 22F, 24F, and 33F
have been identified to have high invasive disease potentials [68, 84, 85]. Studies have also
shown that non-PCV13 15B/C/A, 23B, 24F, 35B are not only important causes of IPD but also
are common nasopharyngeal colonisers and have high prevalence of antibiotic resistance [86–
90]. Considering the important contribution of non-PCV13 serotypes to childhood IPD in
these settings, next generation PCVs with greater coverage will be needed to reduce the
remaining burden of pneumococcal disease.
There is paucity of data on burden of pneumococcal disease in Latin American countries.
Nevertheless, 1,500,000 cases and 28,000 deaths of IPD are estimated to occur annually in chil-
dren less than 5 years of age in Latin America [91]. We analysed data from 10 countries in
Latin America, all from SIREVA surveillance systems, of which 5 currently use PCV10. Com-
pared with other regions, the proportions of IPD caused by vaccine types were highest in this
region. The contribution of PCV7 serotypes for IPD was 10-fold higher in Latin America than
in the North America. Given the predominant role of vaccine types, the expansion of immuni-
sation programmes with PCVs and surveillance of epidemiological changes is critical for effec-
tively reducing the burden of pneumococcal disease in Latin American countries.
Before PCVs became available, the highest proportion of deaths (60%) associated with
childhood IPD were estimated to occur in Africa and Asia [1]. A limited number of coun-
tries in the South East Asian and Mediterranean region have introduced PCVs and are eval-
uating their impact [92]. A recent systematic review of serotypes associated with IPD found
that 1, 14, and 19F were common in South Asian countries. Further, serotypes varied across
countries and there was low prevalence of serotype 19A [93]. We only included serotype
data for two countries from two of these regions—South Africa and Saudi Arabia. In South
Africa, serotype 8 was the most frequent serotype in childhood IPD post-PCV. This is in
contrast to its position during the pre-PCV era in Africa, when its contribution was approxi-
mately 1% of IPD, ranking 8th [5]. Thus, our overall pooled estimates for the so-called Afri-
can and Eastern Mediterranean regions in this study should be interpreted with caution.
Our review of the literature shows that evidence of the effects of PCV in countries in Asia,
Africa, and Eastern Mediterranean is urgently needed to further understand the role of sero-
types following PCV10 and PCV13 introduction in settings with high burden of S. pneumo-
niae disease.
Serotype-specific meta-analysis, as performed in this study, provides evidence on potential
serotypes of interest in the post-PCV era. However, changes in the proportional contribution
of different strains to childhood IPD need to be interpreted carefully and in the context of
changes in IPD incidence in a particular setting. For example, if the percentage of isolates for a
serotype doubled, but the IPD decreased by 50%, it would indicate that there was no change in
the absolute number of cases for particular serotypes. Without incidence data, we are unable
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to indicate if there has been a change in the absolute number of IPD cases in any given sero-
type in the post-PCV era or to account for varying factors, such as temporal changes in the
study population and vaccine utilisation [11]. Yet, evidence in this review and meta-estimates
adds to the information base about serotypes’ individual importance in IPD and emphasise the
need for closer attention to regional differences in the post-PCV era.
Limitations
This study is not exempt from limitations of systematic reviews and meta-analysis. For some
studies, case counts by serotype were not exact as we extracted data from images or calculated
them from proportions. In other instances, serotype data were only available in a grouped for-
mat (e.g. “other”) or not all IPD cases were serotyped/reported. Missing information is likely
to affect serotypes considered “rare” or “infrequent”, which will vary in each setting. These
issues can potentially introduce biases to our results since not all serotypes could be assessed
individually. Our meta-estimates could also be influenced by the differences across studies and
are not exempt from risk of under or over-estimation. Although we sought to include large
studies, datasets were heterogeneous, reported different sample sizes, observed diverse popula-
tions with varying rates of vaccine coverage, immunisation schedules, and methods for case
detection of IPD (either by clinical and testing practices). Additionally, analyses were con-
ducted individually per serotype, thus the sum of serotypes into categories may exceed 100%.
Limitations withstanding, the large number of countries represented and isolates analysed is a
strength of our review. We aimed to address issues of heterogeneity by analysing the most
comparable data and case definitions. We also stratified analysis by PCV formulation and used
data for children of the same age (<5 years) whenever possible. We would recommend future
studies assessing serotype distribution after PCV introduction to report a clear definition and
description of vaccine coverage in order contextualise results and better understand vaccine
impact.
Conclusion
In the post-PCV era, childhood IPD is associated with a wide number of serotypes. After
PCV7 and in the early years after introduction of higher valent PCVs, 19A was the most
commonly identified serotype in different world regions. Non-PCV13 serotypes caused a con-
siderable proportion of childhood IPD, which emphasises the need for new vaccines with addi-
tional serotypes to reduce the remaining burden of childhood pneumococcal disease. Data on
serotypes causing IPD from the regions with the highest burden were not available to draw
robust regional conclusions. The geographic diversity of serotypes and changing epidemiology
of S. pneumoniae underscores the importance of continued surveillance of pneumococcal sero-
types to guide vaccine recommendations.
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